Welcome to our dedicated page for Geron news (Ticker: GERN), a resource for investors and traders seeking the latest updates and insights on Geron stock.
Geron Corporation (GERN) is a clinical-stage biopharmaceutical company advancing novel oncology therapies through its telomerase inhibitor research. This page provides investors and industry professionals with verified updates on clinical developments, regulatory milestones, and strategic initiatives.
Access the latest press releases and analysis related to imetelstat's progress in treating hematologic malignancies like myelodysplastic syndromes. Our curated collection ensures you stay informed about trial results, partnership announcements, and scientific presentations without speculative commentary.
Key updates include details on Phase 3 clinical trials, FDA communications, intellectual property developments, and collaboration agreements. All content is sourced directly from official company channels to maintain accuracy and compliance.
Bookmark this page for streamlined access to Geron's evolving story in cancer therapeutics. Check back regularly for objective reporting on advancements in telomerase-targeted treatment approaches.
Geron Corporation (NASDAQ: GERN) announced that data from the pivotal IMerge Phase 3 clinical trial of its telomerase inhibitor, imetelstat, in lower-risk myelodysplastic syndromes (MDS) is scheduled for oral presentation at the 2023 ASCO Annual Meeting in Chicago. The study evaluates imetelstat in patients who are transfusion dependent and have relapsed or are refractory to erythropoiesis-stimulating agents. The primary efficacy endpoint is the rate of red blood cell transfusion independence lasting at least eight weeks, with secondary endpoints focusing on longer durations and hematologic improvement. The trial enrolled 178 patients across multiple regions. Geron plans to submit a New Drug Application in mid-2023 and a Marketing Authorization Application in the EU later this year.
Geron Corporation (Nasdaq: GERN) has granted non-statutory stock options to acquire 1,684,220 shares of common stock as an employment inducement for newly hired employees. The options were issued on April 19, 2023, at an exercise price of $2.49 per share, equal to the stock's closing price that day. Of the total, 1,586,000 options have a 10-year term and vest over four years, with an initial 12.5% vesting after six months. The remaining shares will vest monthly over the following 42 months. The remaining 98,220 options will vest upon achieving specific regulatory milestones. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and follows Geron’s 2018 Inducement Award Plan.
Geron focuses on therapies for hematologic malignancies, particularly its investigational telomerase inhibitor, imetelstat.
Geron Corporation (Nasdaq: GERN), a biopharmaceutical company focused on hematologic malignancies, announced that John A. Scarlett, M.D., the Chairman and CEO, will participate in fireside chats at two upcoming investor conferences.
- 22nd Annual Needham Virtual Healthcare Conference
Date: April 20, 2023
Time: 10:15 a.m. ET - Stifel 2023 Virtual Targeted Oncology Days
Date: April 25, 2023
Time: 2:00 p.m. ET
Webcasts of the chats will be accessible via the Investor Relations section of Geron’s website and archived for 30 days post-event. Geron is advancing its first-in-class telomerase inhibitor, imetelstat, which aims to impact the treatment of these diseases significantly.